Samsung Bioepis announced on the 27th that Vice President Kim Kyung-ah has been promoted and appointed as CEO.
Newly appointed CEO Kim holds a bachelor's and master's degree in pharmacy from Seoul National University and earned a Ph.D. in toxicology from Johns Hopkins University in the United States. She is an expert in biosimilar development and joined Samsung Electronics' Advanced Institute of Technology as a senior researcher in bio new drug development in 2010. In 2015, she joined Samsung Bioepis and has played a key role across the business, including biosimilar development, processes, quality, and regulatory affairs.
Samsung Bioepis stated that CEO Kim, as the first female professional management CEO in the Samsung Group, is expected not only to present a growth vision to female talents and create opportunities for bold challenges but also to serve as a role model for the women who make up more than half of Samsung Bioepis' workforce, thereby injecting new vitality into the organization.
Samsung Bioepis will soon finalize and announce the regular executive personnel appointments for next year, including positions below vice president.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
